Spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac from the combined capsule dosage form

INTRODUCTION: The present work aimed to develop and validate spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac in a pure and capsule dosage form. MATERIALS AND METHODS: Method 1 is based on solving a simultaneous equation. Absorbances of rabeprazole sodium and aceclofenac were measured at their respective absorbance maximas (λ(max)) of 283 and 276 nm. Method 2 is the Q-analysis or absorption ratio method. Absorbances were measured at 256 nm (isosbestic point) and 276 nm (λ(max) of aceclofenac). Methods are validated according to ICH guidelines. RESULTS: A linearity range for rabeprazole sodium and aceclofenac is 10–60 μg/ml at respective selected wavelengths. The coefficient of correlation for rabeprazole at 283 nm and for aceclofenac at 276 nm is 0.9981 and 0.9997, respectively. A percentage estimation of rabeprazole sodium and aceclofenac from the capsule dosage form by method 1 is 100.22 and 99.96 and by method 2 is 99.99 and 100.05, respectively, with a standard deviation less than 2. CONCLUSION: The proposed methods are simple, rapid, and validated and can be used successfully for routine simultaneous estimation of rabeprazole sodium and aceclofenac in a pure and capsule dosage form.